Cover Image
Market Research Report

Asia Pacific Antihypertensive Drugs Market Forecast 2019-2028

Published by Inkwood Research Product code 943439
Published Content info 128 Pages
Delivery time: 2-3 business days
Price
Back to Top
Asia Pacific Antihypertensive Drugs Market Forecast 2019-2028
Published: June 21, 2020 Content info: 128 Pages
Description

KEY FINDINGS

The Asia Pacific antihypertensive drugs market is set to record a significant CAGR of 4.32% during the forecast period, 2019 to 2028. The market growth is attributed to an increase in health care expenses and awareness about the use of antihypertensive drugs.

MARKET INSIGHTS

The evaluation of Asia Pacific antihypertensive drugs market growth includes the countries namely, India, China, Japan, South Korea, Vietnam, Australia & New Zealand, Thailand, Indonesia, and the rest of Asia Pacific. The aging population in Thailand is predicted to increase to 20 million people, accounting for over 35% of the total population. Moreover, respiratory diseases like Chronic Obstructive Pulmonary Disease (COPD) and asthma are on a constant rise. The upsurge leads to not only an increase in disease burden across the population, but also an increase in economic burden for the nation. This is likely to be responsible for the antihypertensive drugs market growth, over the forecast period. In Vietnam, factors like an increase in pollution levels and the availability and distribution of technologically developed antihypertensive drugs are expected to benefit the market growth. The rise in the geriatric population in the county is also projected to stimulate market growth during the forecast period. Increasing respiratory infections in Indonesia is predicted to further drive the antihypertensive drug market growth in the country.

COMPETITIVE INSIGHTS

Medtronic Plc, Johnson & Johnson, Lupin Limited, Novartis AG, and Sun Pharmaceutical Industries Ltd (Ranbaxy Laboratories), are among the prominent companies, that help drive market growth.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 32279

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. GROWING PREVALENCE OF HYPERTENSION ACROSS THE GLOBE
    • 3.2.2. SURGE IN DISPOSABLE INCOME AND HEALTHCARE SPENDING
    • 3.2.3. RISING AGING POPULATION
  • 3.3. KEY RESTRAINTS
    • 3.3.1. PATENT EXPIRATIONS
    • 3.3.2. DELAY IN PRODUCT LAUNCHES

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. REGULATORY FRAMEWORK
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY DRUG CLASS

  • 5.1. CALCIUM CHANNEL BLOCKERS
  • 5.2. ACE INHIBITORS
  • 5.3. BETA-ADRENERGIC BLOCKERS
  • 5.4. DIURETICS
  • 5.5. VASODILATORS
  • 5.6. OTHER DRUG CLASS

6. MARKET BY END-USER

  • 6.1. HOSPITAL PHARMACY
  • 6.2. RETAIL PHARMACY
  • 6.3. E-COMMERCE WEBSITES & ONLINE DRUG STORES

7. GEOGRAPHICAL ANALYSIS

  • 7.1. ASIA PACIFIC
    • 7.1.1. CHINA
    • 7.1.2. JAPAN
    • 7.1.3. INDIA
    • 7.1.4. AUSTRALIA & NEW ZEALAND
    • 7.1.5. SOUTH KOREA
    • 7.1.6. THAILAND
    • 7.1.7. INDONESIA
    • 7.1.8. VIETNAM
    • 7.1.9. REST OF ASIA PACIFIC

8. COMPANY PROFILES

  • 8.1. ALLERGAN PLC
  • 8.2. ASPIRE BARIATRICS INC
  • 8.3. ASTRAZENECA PLC
  • 8.4. BIO-RAD LABORATORIES INC
  • 8.5. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • 8.6. DAIICHI SANKYO COMPANY LIMITED
  • 8.7. HILL-ROM HOLDINGS INC
  • 8.8. JOHNSON & JOHNSON
  • 8.9. LUPIN LIMITED
  • 8.10. MEDTRONIC PLC
  • 8.11. MERCK & CO INC
  • 8.12. NOVARTIS AG
  • 8.13. PFIZER INC
  • 8.14. SANOFI
  • 8.15. SUN PHARMACEUTICAL INDUSTRIES LTD (RANBAXY LABORATORIES)

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ANTIHYPERTENSIVE DRUGS
  • TABLE 2: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 4: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 6: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, IN 2019
  • FIGURE 6: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY CALCIUM CHANNEL BLOCKERS, 2019-2028 (IN $ MILLION)
  • FIGURE 7: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY ACE INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 8: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY BETA-ADRENERGIC BLOCKERS, 2019-2028 (IN $ MILLION)
  • FIGURE 9: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY DIURETICS, 2019-2028 (IN $ MILLION)
  • FIGURE 10: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY VASODILATORS, 2019-2028 (IN $ MILLION)
  • FIGURE 11: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY OTHER DRUG CLASS, 2019-2028 (IN $ MILLION)
  • FIGURE 12: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, IN 2019
  • FIGURE 13: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY HOSPITAL PHARMACY, 2019-2028 (IN $ MILLION)
  • FIGURE 14: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY RETAIL PHARMACY, 2019-2028 (IN $ MILLION)
  • FIGURE 15: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, BY E-COMMERCE WEBSITES & ONLINE DRUG STORES, 2019-2028 (IN $ MILLION)
  • FIGURE 16: ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 17: CHINA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 18: JAPAN ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 19: INDIA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 20: AUSTRALIA & NEW ZEALAND ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 21: SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 22: THAILAND ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 23: INDONESIA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 24: VIETNAM ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 25: REST OF ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
Back to Top